Is Heart Rate the Missing Target in Hypertension Management?

Persistent Elevated Heart Rate: Independent Predictor of CV Risk in Hypertension

Blood pressure (BP) and heart rate (HR) are closely linked through sympathetic nervous system activity, a key driver of early hypertension pathophysiology and development. Increased sympathetic drive may raise BP while accelerating HR, thereby increasing myocardial workload and vascular stress. Elevated resting HR is now recognized as more than a hemodynamic marker; it has been associated with target organ damage and higher risk of coronary heart disease, heart failure, stroke, sudden cardiac death, and all-cause mortality. ⁴ Elevated HR may also contribute to ischemia, infarction, ventricular remodeling, and heart failure progression (Figure 1). ⁵ Given its prognostic value, routine HR assessment alongside BP may support comprehensive cardiovascular risk evaluation.

Figure 1: Influence of Elevated Heart Rate Across the Cardiovascular Continuum

Blood Pressure & Heart Rate Control, Both Matter in Hypertension: Clinical Evidence Learnings

Effective hypertension management should address both blood pressure (BP) and heart rate (HR). Although BP remains the primary therapeutic target, persistently elevated HR adds cardiovascular risk even when BP is controlled. Together, elevated BP and HR increase myocardial oxygen demand, reduce diastolic coronary perfusion, and accelerate vascular injury.

VALUE Trial: Elevated HR Predicts Cardiovascular Events Beyond BP Control: The VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial followed 15,193 patients with high-risk hypertension for five years. Every 10 bpm increase in baseline HR increased the risk of composite cardiac events by 16% (HR 1.16; 95% CI 1.12–1.20), while patients in the highest HR quintile had a significantly higher risk than those in the lowest quintile (adjusted HR 1.73; 95% CI 1.46–2.04). Importantly, elevated HR was associated with 53% and 34% higher cardiovascular event rates in patients with well-controlled and uncontrolled BP, respectively, demonstrating that its prognostic impact was independent of BP control. ⁶

LIFE Study: Persistently Elevated HR Increases Mortality Risk: The LIFE study followed 9,190 hypertensive patients with electrocardiographic LVH for a mean of 4.8 years. After adjustment for BP reduction, treatment modality, left ventricular hypertrophy regression, and other cardiovascular risk factors, every 10 bpm increase in in-treatment HR remained associated with a 16% higher risk of cardiovascular mortality and a 25% higher risk of all-cause mortality. Persistence or development of HR ≥84 bpm increased the adjusted risk of cardiovascular death by 55% and all-cause mortality by 79%. ⁷

BEAT Survey: Indian Real-World Evidence: The BEAT survey evaluated 3,743 Indian hypertensive patients aged 18–55 years. Mean resting HR was 82.8 ± 10.4 bpm and correlated significantly with systolic (r=0.247; p<0.01) and diastolic BP (r=0.219; p<0.01), but not with age. The investigators concluded that persistently elevated HR is common in Indian hypertensive patients and may contribute to future cardiovascular morbidity and mortality. ⁸

Targeting Dual Hemodynamic Risk: Potential of Telmisartan and Metoprolol

In hypertensive patients requiring control of both blood pressure (BP) and heart rate (HR), combining agents with complementary mechanisms seems clinically rational. Telmisartan, an angiotensin II receptor blocker (ARB), provides sustained 24 hour BP reduction, while metoprolol, a β1-selective beta-blocker, attenuates sympathetic activity and lowers HR. Indian expert consensus recommends β1-selective beta-blockers in hypertensive patients with resting HR >80–85 bpm, with an expected HR reduction of ~10 bpm. ⁹

In a multi-centric, randomized, double-blind phase III trial across 10 Indian centres, 264 patients with stage 1–2 hypertension received fixed-dose telmisartan 40 mg with either metoprolol succinate ER 50 mg or bisoprolol 5 mg for 12 weeks. Telmisartan–metoprolol produced significant systolic and diastolic BP reductions from week 2, with 86.7% achieving target BP (<140/90 mmHg) by week 12 and no serious adverse events reported. The study concluded that the telmisartan–metoprolol combination demonstrated efficacy, safety, and tolerability comparable to the telmisartan–bisoprolol combination, supporting its use as an effective therapeutic option among patients with stage 1–2 hypertension. ¹⁰

Latest Guideline Perspective on Beta-Blocker Use in Hypertension when HR>80 bpm

Guideline	Key Recommendation	Clinical Message
Indian Society of Hypertension (InSH) Consensus Guideline (2025) 11	Recommends individualized antihypertensive therapy with early use of single-pill combinations where appropriate. Beta-blockers remain relevant in patients with compelling cardiovascular indications, including the need for heart-rate control.	Supports patient-specific treatment selection based on BP level, cardiovascular risk, comorbidities, and clinical phenotype.
ESC Guidelines for Elevated BP and Hypertension (2024) 12	Beta-blockers are useful when hypertension coexists with compelling indications such as coronary artery disease, post-MI, heart failure, atrial fibrillation, or need for heart-rate control.	Use selectively when BP control must be combined with cardiovascular or HR control.
ESH Guidelines for Arterial Hypertension (2023) 13	Beta-blockers are included among the five major antihypertensive drug classes and are supported in patients with resting HR >80 bpm.	Elevated HR can guide beta-blocker selection in hypertensive patients.

Key Message

• Blood pressure and heart rate are complementary determinants of cardiovascular risk, and routine assessment of both can improve risk stratification in hypertensive patients.
• Persistently elevated resting heart rate independently predicts adverse cardiovascular outcomes, even in patients who achieve blood pressure targets.
• Evidence from VALUE, LIFE, and BEAT supports that controlling BP alone may not fully address residual cardiovascular risk.
• In appropriately selected patients, therapeutic strategies targeting both BP and HR, such as an ARB combined with a β1-selective beta-blocker, may provide complementary cardiovascular benefits.
• Real-world evidence reiterates telmisartan–metoprolol as a widely utilized ARB + BB combination in Indian hypertension practice, reflecting its clinical importance among patients requiring combined BP and HR control. ¹³

**Abbreviations: BP: Blood pressure; HR: Heart rate; CV: Cardiovascular; CVD: Cardiovascular disease; NFHS-5: National Family Health Survey-5; CAD: Coronary artery disease; HF: Heart failure; LVH: Left ventricular hypertrophy; VALUE: Valsartan Antihypertensive Long-term Use Evaluation; LIFE: Losartan Intervention For Endpoint Reduction in Hypertension; BEAT: Baseline Heart Rate Evaluation in Indian Hypertensives; ARB: Angiotensin II receptor blocker; BB: Beta-blocker; ER: Extended release; InSH: Indian Society of Hypertension; ESC: European Society of Cardiology; ESH: European Society of Hypertension; MI: Myocardial infarction; CI: Confidence interval; bpm: Beats per minute; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.